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Introduction:  Neisseria  meningitidis  causes  epidemics  of  meningitis  in sub-Saharan  Africa.  These  have
mainly  been  caused  by capsular  group  A strains,  but  W  and  X strains  are  increasingly  contributing  to  the
burden  of disease.  Therefore,  an affordable  vaccine  that  provides  broad  protection  against  meningococcal
disease  in sub-Saharan  Africa  is required.
Methods: We  prepared  Generalized  Modules  for Membrane  Antigens  (GMMA)  from  a recombinant
serogroup  W  strain  expressing  PorA  P1.5,2,  which  is  predominant  among  African  W  isolates.  The  strain
was  engineered  with  deleted  capsule  locus  genes,  lpxL1  and  gna33  genes  and  over-expressed  fHbp  variant
1,  which  is  expressed  by  the majority  of serogroup  A and  X  isolates.
Results: We  screened  nine  W  strains  with  deleted  capsule  locus  and gna33  for  high-level  GMMA  release.
A  mutant  with  ﬁve-fold  increased  GMMA  release  compared  with  the  wild  type  was further  engineered
with  a  lpxL1 deletion  and over-expression  of fHbp.  GMMA  from  the  production  strain  had  50-fold  lower
ability  to  stimulate  IL-6 release  from  human  PBMC  and  caused  1000-fold  lower  TLR-4  activation  in Human
Embryonic  Kidney  cells  than  non-detoxiﬁed  GMMA.  In mice,  the  GMMA  vaccine  induced  bactericidal
antibody  responses  against  African  W  strains  expressing  homologous  PorA  and  fHbp  v.1 or v.2  (geometric
mean  titres  [GMT]  = 80,000–200,000),  and  invasive  African  A and  X  strains  expressing  a  heterologous  PorA
and  fHbp  variant  1 (GMT  = 20–2500  and 18–5500,  respectively).  Sera  from  mice  immunised  with  GMMA
without  over-expressed  fHbp  v.1 were  unable  to  kill  the  A and  X strains,  indicating  that  bactericidal
antibodies  against  these  strains  are directed  against  fHbp.
Conclusion: A  GMMA  vaccine  produced  from  a recombinant  African  N.  meningitidis  W strain  with  deleted
capsule  locus,  lpxL1,  gna33  and  overexpressed  fHbp  v.1 has potential  as  an affordable  vaccine  with  broad
coverage  against  strains  from  all main  serogroups  currently  causing  meningococcal  meningitis  in sub-
Saharan  Africa.. Introduction
Neisseria meningitidis is a major cause of epidemics in sub-
aharan Africa [1]. These were mainly caused by strains belonging
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to capsular group A, but there has been an increasing contribu-
tion of serogroups W and X strains with epidemic potential in
the last two  decades [2–5]. A serogroup A polysaccharide con-
jugate vaccine (MenAfriVac) has been developed for preventive
mass immunization in the African meningitis belt [6]. The vaccine
is highly effective at prevention of serogroup A invasive disease
and carriage [7–9], but group W and X strains remain a persistent
Open access under CC BY-NC-ND license.problem. This underlines the need for an affordable vaccine that
provides protection against the main serogroups causing meningi-
tis in Africa and potentially against serogroups that may  emerge in
the region in the future.
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GMMA  generated from strains engineered to over-express
mmunogenic antigens that are present across all serogroups, con-
titute an attractive approach to vaccination. The term GMMA
Generalised Modules for Membrane Antigens) provides a clear dis-
inction from conventional detergent-extracted outer membrane
esicles (dOMV), and native outer membrane vesicle (NOMV),
hich are released spontaneously from Gram-negative bacteria.
MMA differ in two crucial aspects from NOMV. First, to induce
MMA formation, the membrane structure has been modiﬁed by
he deletion of genes encoding key structural components, includ-
ng gna33 (meningococcus) and tolR (Shigella and Salmonella [10]).
econd, as a consequence of the genetic modiﬁcation, large quanti-
ies of outer membrane bud off (the Italian word for bud is ‘gemma’)
o provide a practical source of membrane material for vaccine
roduction, leading to potential cost reduction. While NOMV have
een used for immunogenicity studies, the yields are too low for
ractical vaccines.
The  most promising candidate protein vaccine antigen discov-
red for meningococcus is factor H binding protein fHbp. The
xtraction process required to make dOMV removes lipoproteins,
ncluding fHbp, and increases the cost of production of dOMV
elative to GMMA. The fHbp gene is present in most invasive
eningococcal isolates independent of the serogroup. fHbp can be
ivided into three antigenic variants (v. 1, 2 or 3) [11] or into at
east nine modular groups based on the combination of ﬁve vari-
ble  and  fHbp segments [12,13]. Individual peptides within
ach variant are identiﬁed by a unique peptide ID. The outer mem-
rane protein, PorA, is highly immunogenic but antibodies tend
o provide subtype-speciﬁc protection [14]. African meningococcal
solates are relatively conserved in relation to fHbp variant and PorA
ubtype [15,16]. Invasive serogroup A and X strains predominantly
xpress fHbp v.1. PorA subtype P1.5,2 is shared by most serogroup
 strains and P1.20,9 is expressed by the majority of A strains [15].
his epidemiological pattern makes a protein-based vaccine both
 possible and attractive approach for sub-Saharan Africa.
A  vaccine for the meningitis belt needs to be affordable and
arge-scale low-cost production of a GMMA  vaccine has to be fea-
ible. Deletions of gna33 or rmpM, that augment the release of
hese outer membrane particles can reduce costs [17–21]. In this
tudy, we selected a vaccine strain based on a panel of African W
train capsule and gna33 double knock-out mutants. The isolate
ith the highest GMMA  production was then further engineered
or the deletion of lpxL1 and over-expression of fHbp v.1 (ID1). This
enetic approach may  form the basis for a broadly-protective, safe
nd economic vaccine for sub-Saharan Africa.
. Materials and methods
.1.  N. meningitidis strains
Three African serogroup W,  seven A and seven X strains were
he target strains for serum bactericidal assays. Nine African
erogroup W strains were screened as potential vaccine produc-
ion strains (Table 1). Carrier strain 1630 (ST-11) expressing PorA
ubvariant P1.5,2 and fHbp v.2 (ID23) was chosen for GMMA
roduction [22]. To abolish capsule production, a fragment of the
acterial chromosome containing synX, ctrA and the promoter
ontrolling their expression, was replaced with a spectinomycin-
esistance gene. First, the recombination sites were ampliﬁed with
rimers ctrAf Xma:CCCCCCGGGCAGGAAAGCGCTGCATAG and
trAr XbaCGTCTAGAGGTTCAACGGCAAATGTGC; Synf KpnCGG-
GTACCCGTGGAATGTTTCTGCTCAA and Synr SpeGGACTAGTCCA-
TAGGCCTAAATGCCTG from genomic DNA from strain 1630.
he fragments were inserted into plasmid pComPtac [23]
pstream and downstream of the chloramphenicol resistance gene.32 (2014) 2688–2695 2689
Subsequently the chloramphenicol resistance gene was  replaced
with a spectinomycin resistance cassette. The lpxL1 gene was
deleted by replacement with a kanamycin resistance gene [24],
and the gna33 gene with an erythromycin resistance cassette
[25]. fHbp expression was  up-regulated using multicopy plasmid
encoding fHbp v.1 (ID1) [26].
2.2. GMMA preparation
Bacteria  were grown at 37 ◦C, 5% CO2 in 50 mL  of a modiﬁed
version of a meningococcus deﬁned medium described previously
[27] at 180 rpm until early stationary phase. Cells were harvested
(2200 g, 30 min, 4 ◦C) and the culture supernatant containing the
GMMA  was ﬁltered through a 0.22 m pore-size membrane (Mil-
lipore, Billerica, MA,  USA). To collect GMMA,  the supernatant was
ultracentrifuged (142,000 × g, 2 h, 4 ◦C). The membrane pellet was
washed with phosphate buffered saline (PBS), resuspended in PBS
and sterile ﬁltered. GMMA  concentration was measured according
to protein content by Lowry assay (Sigma–Aldrich, St. Louis, MO,
USA). For protein and lipooligosaccharide analysis, GMMA were
separated by SDS–PAGE using a 12% gel and MOPS or MES  buffer
(Invitrogen, Carlsbad, CA, USA). Total proteins were stained with
Coomassie Blue stain. The amount of PorA was determined by den-
sitometric quantiﬁcation of the PorA protein in relation to total
measurable protein. Lipooligosaccharide was visualized by treat-
ment of the gel with periodic acid and staining with silver nitrate.
The gel was  developed with a solution containing 50 mg/L citric acid
and 0.05% formaldehyde. fHbp was  detected by Western blot using
a polyclonal antibody raised in mice against recombinant fHbp ID1.
2.3. IL-6 release by human peripheral blood mononuclear cells
(PBMC)  stimulated with GMMA
PBMC were separated from whole blood using Ficoll-Paque
Plus density gradient (Amersham Pharmacia Biotec), washed with
PBS and resuspended in 10% heat-inactivated fetal bovine serum
(FBS)/10% Dimethyl sulfoxide and stored in liquid nitrogen until
use. For stimulation, PBMCs were thawed, washed with PBS/2.5 mM
EDTA and 20 g/mL DNAse (Sigma–Aldrich, St. Louis, MO,  USA)
and resuspended in RPMI-1640 complete (with 25 mM HEPES, glu-
tamine, 10% FBS + 1% Antibiotics Pen-Strep). 2 × 105 cells/well were
stimulated with GMMA  (1–10−6g/mL ﬁnal concentration) for 4 h
at 37 ◦C. Cells were removed by centrifugation and IL-6 in the super-
natants was measured by ELISA using 0.1 g of an anti-human IL-6
antibody (eBioscience, San Diego, CA, USA). A Biotin-labelled anti-
human IL-6 antibody was  used for detection (e-Bioscience).
2.4. Measurement of TLR-4 stimulation by NF-B luciferase
reporter assay
Human Embryonic Kidney 293 (HEK293) cells expressing
luciferase under control of the NF-B promoter and stably trans-
fected with human Toll-like receptor (TLR) 4, MD2  and CD14
were used. 25,000 cells/well were added to microclear luciferase
plates (PBI International) and incubated for 24 h at 37 ◦C. GMMA
(1–1.28 × 10−5g/mL ﬁnal concentration) were added and incu-
bated for 5 h. Cells were separated from the supernatant and lysed
with passive lysis buffer (Promega, Madison, WI,  USA). Luciferase
assay reagent (Promega) was added and ﬂuorescence was detected
using a luminometer LMaxII 384 (Molecular Devices).2.5. Mouse immunization
Female  CD-1 mice were obtained from Charles River Laborato-
ries (Wilmington, MA,  USA). Eight mice per group were immunised
2690 O. Koeberling et al. / Vaccine 32 (2014) 2688–2695
Table  1
Characteristics of African N. meningitidis wild type strains used for screening of GMMA  production strains and in serum bactericidal assays.
Strain Serogroup Year of
isolation
Country  Source Sequence
type
fHbp
varianta
fHbp peptide IDa (%
identity to fHbp ID1)
PorA
subtype
fHbp
expression
(%)b
N. meningitidis wild type strains used for screening of the GMMA  production strain
1485 W 2003 Ghana Carrier 11 2 23 5,2
1630 W 2004 Ghana Carrier 11 2 23 5,2
1629 W 2004 Ghana Carrier 11 2 23 5,2
1681 W 2004 Ghana Case 11 2 23 5,2
1682 W 2004 Ghana Case 11 2 23 5,2
1846 W 2004 Ghana Case 11 2 23 5,2
1888 W 2004 Ghana Carrier 11 2 23 5,2
1973 W 2005 Ghana Carrier 11 2 23 5,2
2882 W 2007 Ghana Carrier 11 2 22 5,2
N. meningitidis wild type strains used in serum bactericidal assays
Mali  10/09 W 2009 Mali Case 11 2 23 (70) 5,2 70
BF2/11  W 2011 Burkina Faso Case 11 1 9 (94) 5,2 42
N1361  A 2002 Ghana Case ND 1 5 (96) 20,9 80
N2008  A 2005 Ghana Case ND 1 5 20,9 75
BF6/06  A 2006 Burkina Faso Case 2859 1 5 20,9 52
N2181  A 2006 Burkina Faso Case ND 1 5 20,9 75
Su14/07  A 2007 Sudan Case 7 1 5 20,9 40
N2602  A 2007 Burkina Faso Case ND 1 5 20,9 76
Mali21/10  A 2010 Mali Case 8639 1 5 20,9 33
BF2/97  X 1997 Burkina Faso Case 751 1 73 (93) 5-1,10-1 50
BF12/03  X 2003 Burkina Faso Case 751 1 73 5-1,10-1 53
MRS2006093  X 2006 Ghana Case 181 1 74 (93) 5-1,10-1 75
Ug9/06  X 2006 Uganda Case 5403 1 74 19,26 200
BF7/07  X 2007 Burkina Faso Case 181 1 74 5-1,10-1 160
Ug11/07  X 2007 Uganda Case 5403 1 74 19,26 4
BF16/10  X 2010 Burkina Faso Case 181 1 74 5-1,10-1 101
a Determined by sequencing of the fHbp gene and analysis of the protein sequence using the N. meningitidis database on http://pubmlst.org/neisseria/fHbp/.
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ntraperitoneally three times with 2 weeks intervals. Serum sam-
les were obtained 2 weeks after the third dose. GMMA  from the
erogroup W Triple KO (lpxL1, capsule, gna33 KO), OE fHbp strain
ere given at 0.2, 1 and 5 g doses based on total protein. Two
ther groups of mice received 5 g of GMMA  from the Double KO
lpxL1, gna33 KO) OE fHbp mutant or 5 g GMMA from the Triple
O mutant strain. Control mice were immunised with 5 g recom-
inant fHbp ID1 or aluminium hydroxide only. All vaccines were
dsorbed on 3 mg/mL  Aluminium hydroxide in a 100 L formula-
ion containing 10 mM  Histidine and 0.9 mg/mL  NaCl. Sera were
tored at −80 ◦C until use. All animal work was approved by the
talian Animal Ethics Committee (AEC project number 14112011).
.6.  Serological analysis
Anti-fHbp  IgG antibody titres were measured by ELISA as
reviously described [28]. The coating antigen was 1 g/mL non-
ipidated recombinant hexa-Histidine-tagged fHbp ID1 [11]. Serial
ve-fold dilutions of the serum samples starting at 1:100 were
nalysed. Secondary antibody was a 1:2000 dilution of alkaline
hosphatase-conjugated goat-anti mouse IgG (Invitrogen, cat, no
2-6522, Lot 437983A). The titre was deﬁned as the extrapolated
ilution resulting in absorption of 1 at 405 nm after 30 min  of
ncubation with 1 mg/mL  4-nitrophenyl phosphate disodium salt
exahydrate (Sigma–Aldrich) diluted in 1 M diethanolamine and
.5 mM MgCl2, pH 9.8.
Serum bactericidal antibody (SBA) activities were measured as
escribed before [28]. Bacteria were incubated at 37 ◦C, 5% CO2
n Mueller–Hinton broth containing 0.25% glucose and 0.02 mM
ytidine-5′-monophospho-N-acetylneuraminic acid sodium salt
Sigma–Aldrich). The cells were washed with Dulbecco’s PBS
uffer (Sigma–Aldrich) containing 1% BSA. Each reaction mixture
ontained approximately 400 colony-forming units, 20% humanribed [1]. Percentage expression is in relation to group B strain H44/76, a relatively
rcentage of fHbp expression in group B strain 8047, a relatively high expresser of
complement  screened for lack of bactericidal activity against the
target strain and serial dilutions of the serum samples starting at
1:10. Bactericidal titres were deﬁned as the reciprocal extrapolated
dilution resulting in 50% killing of bacteria after 60 min  incubation
at 37 ◦C compared to the mean number of bacteria in ﬁve control
reactions at time 0.
2.7.  Statistical analysis
For  statistical analysis, antibody titres were log 10 transformed.
ELISA titres <100 were assigned the value 50, SBA titres <10 were
assigned the value 5. Mann–Whitney U test was  used to compare
pairs of values. A probability value of <0.05 was considered statis-
tically signiﬁcant. The analysis was performed with the Graph Pad
Prism software 5.01.
3.  Results
3.1. Selection of the serogroup W GMMA production strain and
generation  of mutants
Nine  group W strains (six carrier and three case isolates) with
PorA subtype P1.5,2, collected in Ghana between 2003 and 2007,
were screened as candidate GMMA  production strains. To iden-
tify the isolate with highest GMMA  production, gna33 was deleted
from all strains. In some isolates, simultaneous deletion of the cap-
sule decreased the GMMA  release compared to the gna33 single
knock-out (KO). Therefore, we generated gna33 and capsule double
KO mutants of the nine W strains and compared GMMA  produc-
tion. These double-mutant strains released two to ﬁve-fold higher
amounts of GMMA  than a representative group W wild type strain
(Fig. 1A). Strain 1630 (gna33 KO, capsule KO), which released the
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Fig. 1. GMMA release by engineered meningococcal W strains A. W strains
engineered  to have deleted capsule and gna33 KO were grown in small-scale
shake-ﬂasks.  Strain 1630 was selected as the GMMA-production strain for further
studies. WT = GMMA  release by a representative wild type strain. Bars indicate
the mean and standard error of three independent experiments. B. Upper panel:
SDS–PAGE and Coomassie Blue stain of 5 g GMMA.  Middle panel: Silver stain of
Table 2
N.  meningitidis vaccine strains and GMMA  vaccines used in the study.
Vaccine strain characteristics Designation of vaccine
strain  and GMMA  used
for  immunization
Prototype vaccine candidate
Serogroup  W,  strain 1630
Capsule  KO, lpxL1 KO, gna33 KO,
over-expressed fHbp ID1
Triple KO, OE fHbp
Control  vaccines
Serogroup W,  strain 1630
Capsule  expressed, lpxL1 KO, gna33 KO,
over-expressed fHbp ID1
Double KO, OE fHbpSerogroup W,  strain 1630
Capsule  KO, lpxL1 KO, gna33 KO
Triple KO
highest quantity of GMMA,  was selected for further genetic manip-
ulation.
To generate the ﬁnal vaccine strain, we deleted lpxL1 and engi-
neered the mutant to over-express fHbp v.1, designated ‘Triple
KO, OE fHbp’. We  also prepared two isogenic group W control
strains: one with deleted lpxL1 and gna33, over-expressed fHbp
v.1 with the capsule still expressed (‘Double KO, OE fHbp’), and
another with deleted lpxL1, capsule and gna33, but no fHbp over-
expression (‘Triple KO’) (Table 2). SDS–PAGE and Coomassie Blue
staining of the proteins revealed a similar protein pattern in the
three GMMA  preparations. Densitometry indicated that in all three
GMMA  preparations, the relative amount of PorA to total pro-
tein is 5%. By silver stain, the GMMA  contained similar levels of
lipooligosaccharide. By capture ELISA, with recombinant fHbp as
standard, approximately 3% of the total protein in GMMA from the
Triple KO, OE fHbp was  fHbp, and by Western blot, the two GMMA
over-expressing fHbp had similar fHbp levels.
3.2. IL-6 release by human PBMC and TLR-4 activation in HEK293
cells after stimulation with GMMA
To assess the endotoxic activity of the GMMA,  we  measured
the release of IL-6 by human PBMC after stimulation with differ-
ent concentrations of GMMA  from the Triple KO,  OE fHbp mutant
and the parent serogroup W wild type strain (Fig. 1C). Approxi-
mately 50-fold higher concentrations of GMMA from the mutant
strain were required to stimulate the release of 200 pg/mL IL-6, con-
ﬁrming the decrease in endotoxic activity. We  measured the ability
of the GMMA  to stimulate human TLR-4 in transfected HEK293 cells
(Fig. 1D). Low concentrations of GMMA  from the wild type bacte-
ria stimulated TLR-4, as measured by increased NF-B expression.
Approximately 1000-fold higher concentrations of GMMA from the
Triple KO, OE fHbp mutant were required for equivalent TLR-4
stimulation. These results are consistent with a strongly decreased
ability of the LOS in GMMA  from the serogroup W mutant to
lipooligosaccharide in 0.5 g GMMA.  Lower panel: detection of fHbp in GMMA
by  Western blot using a polyclonal anti-fHbp v.1 antibody. M = molecular weight
marker.  Lane 1, GMMA  Triple KO, OE fHbp; lane 2, GMMA  Double KO, OE fHbp;
lane  3, GMMA Triple KO. C. IL-6 release by human PBMCs stimulated with different
concentrations  of GMMA  with deleted capsule, gna33 and lpxL1 and over-expressed
fHbp  v.1 for four hours. IL-6 release into culture supernatants was analysed by ELISA.
D. Stimulation of TLR-4 in HEK293 cells transfected with human Toll-like receptor
(TLR)  4, MD2 and CD14 and luciferase expressed under control of the NF-B pro-
moter. Cells were stimulated with GMMA  for ﬁve hours, lysed and emitted light
was quantitated with a luminometer. The readings were divided by the control
cells  stimulated with PBS. Mean results and standard deviations from two indepen-
dent  experiments were plotted. Black circles = GMMA  from the group W wild type
strain 1630 used to construct the mutants. White triangles = Triple KO, OE  fHbp:
GMMA  from the group W mutant strain with deleted capsule, lpxL1 and gna33 and
over-expressed fHbp ID1.
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Fig. 2. IgG anti-fHbp antibody responses elicited in mice as measured by ELISA.
Groups  of eight mice were immunised with three doses of vaccine, 2 weeks apart.
The serum samples analysed were obtained 2 weeks after the third dose. Each sym-
bol represents an individual serum sample, the line indicates the geometric mean
titre of each vaccine group. GMMA  used for immunization: Triple KO, OE fHbp: cap-
sule, lpxL1 and gna33 KO with over-expressed fHbp ID1. Double KO, OE fHbp: lpxL1
and gna33 KO with over-expressed fHbp ID1 and capsule expression. Triple KO:
capsule, lpxL1 and gna33 KO without over-expressed fHbp. rHis-fHbp: recombinant
hexa-histidine  tagged fHbp ID1; Alum: aluminium hydroxide. Numbers above the
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Fig. 3. Serum bactericidal antibody responses of immunised mice against African
meningococci  group W (panel A), group A (panel B) and group X strains (panel C)
measured with human complement. Group A and X strains were ordered based on
their relative fHbp expression, increasing from the left to the right. Serum sam-
ples analysed were obtained 2 weeks after the third dose (see legend to Fig. 4). The
bars show reciprocal geometric mean titres (±95% conﬁdence interval) from four
serum samples per GMMA  vaccine group, containing sera from two mice each. For
the strains labelled with an asterisk and the negative control group (Alum) two
serum pools were analysed containing sera from four mice each and error bars indi-
cate the standard error of the mean. GMMA  vaccines: Triple KO, OE fHbp: capsule,
lpxL1  and gna33 KO with over-expressed fHbp ID1, hatched bars. Triple KO: capsule,
were able to kill all serogroup X strains tested (GMT = 18–5500)-axis show the vaccine dose in g. Statistical analysis between pairs of groups was
y Mann–Whitney U test.
ctivate TLR-4 compared with GMMA  from the non-detoxiﬁed par-
nt wild type strain.
.3.  Antibody responses elicited in mice immunised with GMMA
We  measured anti-fHbp v.1 antibody responses in individual
erum samples by ELISA. GMMA  from all mutants with over-
xpressed fHbp elicited high anti-fHbp antibody responses, even
t the lowest dose of 0.2 g (Fig. 2). 5 g Triple KO, OE fHbp GMMA
nduced signiﬁcantly higher geometric mean titres than 5 g Dou-
le KO, OE fHbp GMMA (P = 0.03) or 5 g of recombinant fHbp v.1
P < 0.001). GMMA  from the Triple KO mutant without fHbp over-
xpression induced no measurable anti-fHbp antibody responses.
.4.  SBA responses of mice immunised with GMMA  from
ecombinant serogroup W strains
The three serogroup W test strains were isolated in Ghana, Mali
nd Burkina Faso and expressed PorA subtype P1.5,2, which is iden-
ical to that expressed by the GMMA  vaccine strains. Strain BF2/11
xpressed fHbp v.1 (ID9) and the two other strains expressed fHbp
.2 (ID23). The seven group A strains tested were collected in Ghana,
urkina Faso, Sudan and Mali. They expressed a heterologous PorA
ompared to that in the GMMA,  and fHbp v.1 (ID5). fHbp expression
n these test strains ranged from 33 to 80% of that of a reference
roup B strain H44/76 with relatively high fHbp expression [11].
he seven group X strains were isolated in Burkina Faso, Ghana
nd Uganda. Two strains from Burkina Faso expressed fHbp ID73,
he other isolates expressed ID74. The strains from Burkina Faso
ere sequence type 751 and 181, respectively. The two  strainsrom Uganda were ST5403 and expressed PorA subtype P1.19,26,
hile the other ﬁve group X strains were P1.5-1,10-1. The two
trains from Uganda differed from each other by the level of fHbplpxL1 and gna33 KO without over-expressed fHbp, grey bars. rHis-fHbp: recombi-
nant  hexa-Histidine tagged fHbp ID1, white bars; Alum: aluminium hydroxide, black
bars. Dotted lines indicate the lowest serum dilution tested (1:10).
expression. Strain Ug11/07 had 4% and Ug9/06 has 200% of the fHbp
expression level compared to the reference strain (Table 1).
GMMA  with or without fHbp over-expression elicited high
bactericidal titres that were not signiﬁcantly different from each
other against the three W strains expressing either fHbp v.1 or
v.2 (Fig. 3A). This is consistent with previous observations that
bactericidal activity against strains sharing the same PorA as the
GMMA-production strain is predominantly mediated by anti-PorA
antibodies [26].
GMMA  from the Triple KO, OE fHbp strain induced antibodies
that were able to kill six out of seven serogroup A strains (geometric
mean titres [GMT] ranging from 20 to 2500) (Fig. 3B). The only iso-
late that was  resistant to killing was  readily killed by a mouse serum
raised against group A polysaccharide conjugate vaccine. The anti-
bodies induced by the GMMA  from the Triple KO, OE fHbp strain(Fig. 3C). GMMA  produced from the W strain which lacked fHbp
v.1 over-expression (Triple KO), induced antibodies that were only
able to kill one X strain (BF7/07), consistent with the majority of
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Fig. 4. Serum bactericidal antibody responses induced by meningococcal W GMMA
A. Dose-dependent serum bactericidal antibody responses induced by group W
triple KO, OE fHbp GMMA  (capsule, lpxL1 and gna33 KO, over-expressed fHbp ID1)
measured with human complement. Mice were immunised three times 2 weeks
apart with 0.2 g (white bars), 1 g (hatched bars) or 5 g (squared bars). Serum
samples  were obtained 2 weeks after the third dose and four pools containing
sera  from two mice each were measured against African serogroup W strain 1630,
serogroup A strain N2602 and serogroup X strain BF7/07. The dotted line indicates
the  lowest serum dilution tested (1:10). Spearman Rank test was used for the statis-
tical analysis of the correlation between the dose and geometric mean titres of each
strain. B. Serum bactericidal antibody responses elicited by GMMA  from W with
or without expression of capsule against one African serogroup W,  two  serogroup
A and three serogroup X strains. GMMA  vaccine groups: Triple KO, OE fHbp: cap-
sule, lpxL1 and gna33 KO with over-expressed fHbp ID1, checked bars. Double KO,
OE fHbp: lpxL1 and gna33 KO with over-expressed fHbp ID1 and capsule expression,
white  bars. Statistical analysis between pairs of groups was done by Mann–Whitney
U  test and asterisks indicate probability values of <0.05. The bars show reciprocal
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rent study was to serve as a ﬁrst proof of concept in mice for aeometric mean titres (±standard error of the mean) from four serum samples per
MMA vaccine group, containing sera from two mice each.
actericidal antibodies induced by the GMMA  vaccine being
irected against fHbp. Antibodies made against the recombinant
Hbp ID1 were only bactericidal against serogroup X strain Ug9/06
ith the highest fHbp expression.
We investigated the dose-dependent bactericidal antibody
esponse against one W (1630), A (N2602) and X (BF7/07) iso-
ate (Fig. 4A). Sera raised against GMMA  with over-expressed fHbp
ere bactericidal against these strains in a dose-dependent man-
er (Spearman Rank P = 0.001 for group A and P < 0.0001 for group
 and X) with killing occurring at all three doses (0.2, 1 and 5 g).
MMA from the triple KO, OE fHbp mutant was prepared from a
utant with deleted capsule expression in order to attenuate viru-
ence of the vaccine strain and reduce serogroup-speciﬁc antibody
roduction. To test the latter, we investigated whether maintain-
ng capsule expression in the GMMA-producing strain affects the
actericidal antibody response. Sera from mice immunised with
MMA prepared from the Triple KO, OE fHbp vaccine strain had sig-
iﬁcantly higher SBA activity against three of ﬁve A and X strains
ested than GMMA  from the isogenic mutant that expressed the32 (2014) 2688–2695 2693
capsule (Fig. 4B). These data are consistent with the hypothesis that
deletion of capsule biosynthesis in the GMMA-production strain
not only decreases virulence, but also increases antibody responses
towards non-capsular antigens, such as fHbp.
4. Discussion
The group A polysaccharide conjugate vaccine, MenAfriVac, is
highly effective at prevention of serogroup A invasive disease and
carriage [7–9]. However, other serogroups, in particular W and
more recently X, are increasingly contributing to the burden of
meningococcal disease in sub-Saharan Africa [3,29–32]. Addition-
ally, other meningococcal serogroups, e.g. group C, that, although
not having caused outbreaks in recent years, may  become a threat
in the future. The challenge for future vaccine approaches for the
meningitis belt is to develop a meningococcal vaccine that is not
only affordable, but provides broad cross-serogroup protection
against meningococcus, and complements the roll out pneumo-
coccal vaccination to deal with the problem of pneumococcal
meningitis in the region.
GMMA  from recombinant meningococcal strains offer a promis-
ing option. They contain protein antigens (e.g. fHbp) which
induce antibodies with serogroup independent cross protec-
tion. In addition, a simple, economic and scalable procedure for
their preparation has been developed with minimal downstream
processing required, which enables large quantities of GMMA  vac-
cine to be produced at low cost [10]. While strains containing
deletions of lpxL1 and capsule synthesis genes with up-regulated
fHbp expression have been described [33,34], our approach incor-
porates the additional deletion of gna33 in order to enhance
the level of GMMA  production, and consequently the potential
affordability of the vaccine for use in Africa. The mechanism of
up-regulation of GMMA  production is not fully understood. Our
ﬁndings indicate that GMMA  release by different gna33 KO strains
is variable, indicating a requirement to screen multiple strains for
high level GMMA  release.
We  tested bactericidal activity of sera from immunised mice
against 17 group A, W and X strains. Five g of the GMMA  from
the Triple KO, OE fHbp group W strain induced SBA responses
against 16 (94%) of these isolates. Ability to kill the A and X strains
was attributable to fHbp which comprises only about 3% of the
total GMMA  protein. In comparison, 5 g recombinant fHbp ID1
induced a detectable bactericidal antibody response only against
one X strain which had the highest level of fHbp expression. This
is consistent with previous studies with NOMV demonstrating that
fHbp expressed in the native membrane environment induces anti-
bodies with greater functional activity than vaccines containing
recombinant fHbp [15,35,36].
Previous  studies have demonstrated broad cross-protection of
NOMV vaccines against a panel of diverse African strains [15,34,37].
We did not compare our GMMA  vaccine directly with NOMV. Nev-
ertheless, the strong bactericidal activity of the GMMA-induced
antibodies against strains with homologous or heterologous PorA
and different fHbp ID types (ID 5, 73 and 74), suggests that the
new combination of mutations, including deletion of gna33, that
all affect the outer surface, does not impair the immunogenicity of
the main antigens, fHbp and PorA. It has been shown that decreased
SBA titres are induced when mice expressing human factor H are
immunised with NOMV over-expressing wild type fHbp [38]. This
can be overcome by introducing the R41S mutation into the fHbp
gene of the vaccine-producing strain [38,39]. The aim of the cur-GMMA meningococcal candidate vaccine and the R41S mutation
was not incorporated into our vaccine design. We are currently
investigating the utility of this mutation in GMMA  vaccines.
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For safety and immunological reasons, we engineered the vac-
ine strain to have deleted lpxL1 and be non-encapsulated which
s associated with the inability to cause invasive disease [40]. As
escribed for group B strains, deletion of lpxL1 resulted in decreased
bility of the group W GMMA  to stimulate Il-6 release by human
BMC and activate TLR-4. These data indicate that genetic detoxi-
cation of meningococcal LOS by inactivation of lpxL1 is a common
echanism among different serogroups.
Consistent with our hypothesis that removal of the capsule
ould enhance the level of bactericidal activity induced against
on-W serogroups, GMMA  produced by the non-encapsulated
utant W strain induced higher bactericidal titres against A and
 strains, than the isogenic encapsulated control. The underlying
echanisms require further investigation. Capsular polysaccha-
ide on GMMA  may  mask fHbp epitopes from the immune system,
articularly from fHbp-speciﬁc B cells. An alternative explanation
s that capsular polysaccharide on GMMA  may  serve as an anti-
enic competitor, interfering and decreasing the immune response
o common protein antigens such as fHbp, although addition of
xternal group A polysaccharide conjugate did not impair antibody
esponses to protein antigens in a meningococcal NOMV vaccine
34]. Thermostability is also highly desirable for any new vaccine
argeted at the African meningitis belt and we are currently inves-
igating this quality in our GMMA  vaccine.
In conclusion, the ﬁndings of this study provide support for
 GMMA-based vaccine approach as an affordable and broadly-
rotective vaccine strategy against meningococcal meningitis for
frica.
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